Image from Changchun High-tech Announcement
Affected by the "heightening needle" incident, the market value of Changchun High-tech (000661) evaporated by 12.4 billion yuan in a single day. On the evening of August 6, Changchun high-tech shareholders, directors and supervisors collectively dispatched to "cheer up" investors, planning to increase their holdings in listed companies by 30 million to 50 million yuan. Beijing Business Daily reporter noted that a total of 8 people participated in the Changchun high-tech shareholding plan, of which Jin Lei, a shareholder who had previously reduced his holdings sharply and was questioned by investors, was listed.
8 people "group" to increase holdings
A total of 8 people participated in Changchun Gaoxin's shareholding increase plan.
On the evening of August 6, Changchun High-tech Disclosure Announcement showed that on August 6, 2021, the company received More than 5% shareholder Jin Lei, the company's current directors Ma Ji, Jiang Yuntao, Wang Zhigang, supervisor Zhao Shuping, senior management li Xiufeng, Zhu Xinggong, Zhang Deshen notice, based on confidence in the company's future sustainable development prospects and recognition of the company's investment value, plans to within 6 months from the date of disclosure of the announcement (legal, Except for the period during which the relevant provisions of the regulations and the business rules of the Shenzhen Stock Exchange are not allowed to increase holdings) to increase the holding of the company's shares through the Shenzhen Stock Exchange trading system with its own or self-raised funds, the total amount of the increase is not less than 30 million yuan, not higher than 50 million yuan.
According to Changchun Gaoxin's 2020 annual report, Li Xiufeng is the company's deputy general manager, 52 years old; Zhu Xinggong is the company's deputy general manager and financial director, 54 years old; Zhang Deshen is the company's board secretary, 56 years old. In response to related questions, the Beijing Business Daily reporter called the office of the secretary of the changchun high-tech board of directors for an interview, but no one answered.
It is worth mentioning that in the keyword "increase in holdings" to search, this is also the first time that Changchun High-tech disclosed the announcement of shareholders and executives' increase in shareholding plans, and there were also cases of executives increasing their holdings before, but the amount of holdings was not high.
Xu Xiaoheng, an investment and financing expert, told the Beijing Business Daily reporter that the increase in shareholders, directors and supervisors can boost investors' investment confidence and is a common measure for listed companies to maintain stock prices.
In the past, Jin Lei, a large household that reduced its holdings, participated
The Beijing Business Daily reporter noted that Jin Lei, who had previously reduced his holdings in Changchun High-tech and was questioned by investors, also participated in the increase plan.
On May 20 this year, Jin Lei reduced his shareholding in the listed company by 4.1242 million shares, and the current shareholding ratio is 8.4997%. Due to the large number of shares to be reduced, at that time, some investors asked on the interactive easy: "Jin Lei reduced his shares by nearly 4 billion yuan, is he not optimistic about the development of the company?" Or is there another reason? Changchun High-tech responded that "after preliminary confirmation with Jin Lei, the reason for the reduction is some other personal capital needs after paying taxes."
In addition to Jin Lei, in the 6 months before the announcement, Jiang Yuntao, Wang Zhigang, Li Xiufeng, Zhu Xinggong, Zhang Deshen and other 5 people also reduced their holdings in Changchun High-tech shares. Specifically, Jiang Yuntao, Wang Zhigang, Li Xiufeng, Zhu Xinggong and Zhang Deshen all reduced their holdings in Changchun Gaoxin in February this year, with the number of shares reduced was 5650 shares, 11625 shares, 11475 shares, 11451 shares and 4600 shares, and the current number of shares held accounted for 0.0042%, 0.0086%, 0.0085%, 0.0085%, and 0.0074% of the total share capital.
Director Ma Ji and supervisor Zhao Shuping both increased their holdings in Changchun Gaoxin in May this year, with the number of shares increased by 5700 shares and 1100 shares respectively, and the current number of shares held accounted for 0.0052% and 0.0013% of the total share capital.
The stock price has almost cut to the waist
Behind the collective increase in shareholders, supervisors and executives, Changchun High-tech stock price has been lower one after another, of which the company's stock price has fallen and closed on August 5 due to the "high needle" incident.
Late on the night of August 4, Xinhua News Agency published an article saying that in recent years, the medical treatment of "height increase injections" mainly used for short stature has quietly emerged, and the investigation found that the so-called "height injections" are actually injections of growth hormone. Experts believe that growth hormone has signs of abuse, which may bring users endocrine disorders, femoral head slippage, scoliosis and other health risks. In recent years, with the increase in social demand, the use of growth hormone has become more and more large. The annual income of a leading domestic growth hormone company has increased year after year. In the five years from 2016 to 2020, its annual income increased more than 4 times, and more than 90% of its revenue came from growth hormone-related products.
As soon as the article came out, investors quickly pointed the spearhead at changchun high-tech companies in A-share listed companies.
It is understood that Changchun High-tech subsidiary Kinsey Pharmaceutical is mainly engaged in the research and development, production and sales of genetically engineered biological drugs, the main products are recombinant human growth hormone for injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-acting water injection) and other growth hormone series products and assisted reproduction, women's health and other fields of products.
Changchun Gaoxin's 2020 annual report shows that the company's operating income is about 8.577 billion yuan, an increase of 16.31% over the same period of the previous year; the corresponding attributable net profit is about 3.047 billion yuan, an increase of 71.64% year-on-year. In addition, the data shows that Kinsey Pharmaceutical, a subsidiary of Changchun High-tech, achieved revenue of 5.803 billion yuan, an increase of 20.34% year-on-year; corresponding to a net profit of 2.76 billion yuan, an increase of 39.66% year-on-year.
According to calculations, in 2020, the subsidiary Kinsey Pharmaceutical contributed 67.66% of the revenue to Changchun High-tech.
On August 5, Changchun Gaoxin's stock price fell to a halt and closed without suspense, and the company's total market value evaporated by 12.4 billion yuan in only one trading day. On August 6, Changchun High-tech stock price also maintained a low-level shock trend, but finally turned red in the afternoon, as of the close of the day, the company's stock price was reported at 278.04 yuan / share, a slight increase of 0.55%.
Looking at the Changchun high-tech stock price from a long perspective, after entering the middle of May, it is in a state of continuous decline. According to the statistics of Oriental Wealth Data, in the 58 trading days from May 18 to August 6 this year, the cumulative decline between Changchun High-tech Zones reached 46.53%, and the market rose by 2.57% in the same period.
Whether this increase in holdings can save the stock price trend of listed companies that have "fallen and fallen" will take time to verify.
Beijing Business Daily reporter Ma Changchang
![Scarce large flats in the middle of the city! This is the real trump card of Jin Lei Phoenix[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)